Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
International Journal of Clinical Practice Oct 28, 2017
Citrome L - The intent of this study was to illustrate the efficacy, tolerability and safety of deutetrabenazine for the treatment of tardive dyskinesia (TD). Deutetrabenazine served as the second FDA-approved agent particularly for the treatment of TD. Head-to-head comparisons were warranted with other vesicular monoamine transporter type 2 (VMAT2) inhibitors among patients with TD in the Âreal world setting.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
